Literature DB >> 33060151

Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma.

Alberto Papi1, Irene Braithwaite2, Stefan Ebmeier2, Robert J Hancox3,4, Tim Harrison5, Mark Holliday2, Claire Houghton2, Luca Morandi1, Karen Oldfield2, Ian D Pavord6, Helen K Reddel7, Mathew Williams2, Mark Weatherall8, Richard Beasley2,9.   

Abstract

Entities:  

Year:  2021        PMID： 33060151     DOI： 10.1183/13993003.03064-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  3 in total

1.  ERS International Virtual Congress 2021: Highlights from the Turkish Thoracic Society Early Career Members.

Authors:  Merve Yumrukuz Şenel; Dilek Karadoğan; Ilgım Vardaloğlu; Elif Develi; Selma Çelik; Mina Hızal; Beste Özsezen; Aslı Öncel; İlknur Can; Nur Hürsoy; Kübra Uyar; Fatma Gülsüm Karakaş; Berrin Er; Pelin Asfuroğlu; Tuğba Ramaslı Gürsoy; Tuğba Şişmanlar Eyüboğlu; Eylül Pınar Çakır; Dilber Ademhan; Selen Karaoğlanoğlu; Nagehan Emiralioğlu; Nilufer Aylin Acet Öztürk; Feride Marim; Özge Aydın Güçlü; Nazli Çetin; Dilara Ömer Topçu; Pınar Çelik; Metin Akgün
Journal:  Turk Thorac J       Date:  2022-03

2.  Is It Really Feasible to Use Budesonide-Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis.

Authors:  Xiang Tong; Tao Liu; Zhenzhen Li; Sitong Liu; Hong Fan
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

3.  Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study.

Authors:  Juliet Foster; Richard Beasley; Irene Braithwaite; Tim Harrison; Mark Holliday; Ian Pavord; Helen Reddel
Journal:  BMJ Open       Date:  2022-01-21       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.